Diabetic Retinopathy Market Scope
Diabetic Retinopathy is a diabetes complication that affects eyes, this condition damages the blood vessels of the light-sensitive tissue on retina. Diabetes mellitus, a devastating illness that has reached epidemic proportions, is causing an increase in severe retinal problems around the world. Published literatures suggest that the number of diabetic conditions are estimated to more than double by 2040. Retinal disorders are prevalent among patients with Type 1 or Type 2 diabetes. Emerging regions leading including Asian economies comprising of huge portion of diabetic population. All these factors account for market growth potential for Diabetic Retinopathy.
The Diabetic Retinopathy market study is segmented by Type (Laser surgery, Injection of corticosteroids, Anti-VEGF drugs and Vitrectomy), by Application (Hospitals, Clinics and laboratories and Others) and major geographies with country level break-up.
The Diabetic Retinopathy market is highly consolidated, companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Diabetic Retinopathy market throughout the predicted period.
Abbott Laboratories (United States), Alimera Science (United States), Allergan PLC (India), Ampio Pharmaceuticals (United States), Bayer AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Pfizer (United States), Regeneron Pharmaceuticals Inc. (United States) and Bausch Health (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are NovaGo Theraputics (Switzerland) and Eyenuk (United States).
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
AdvanceMarketAnalytics has segmented the market of Global Diabetic Retinopathy market by Type, Application and Region.
On the basis of geography, the market of Diabetic Retinopathy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Leaders and their expansionary development strategies
On 21st September, 2020 - Bausch Health Acquired Option to Purchase Ophthalmology Assets of Allegro Ophthalmics, the Agreement Includes Global Rights for Risuteganib/Luminate (Allegro’s Key Retinal Investigation Compound). This Addition is Intended to Enhance Bausch’s Retinal Treatment Portfolio. and On 16th November, 2020 – Pfizer Completed Spinoff of its UPJohn Business with Mylan (Leading Specialty Pharmaceuticals Company), this Intended Spin-off is Aimed to Expand Pfizer’s Prevention and Treatment Capabilities across Segments Including Eyecare.
On 5th August, 2020 - Eyenuk Announced FDA Clearance for its “EyeArt” an Autonomous Artificial Intelligence (AI) Based System Designed for Diabetic Retinopathy Screening. and On 3rd February, 2021 – NovaGo (Biotech Start-up) Started Clinical Trials For its New “Fully Human Antibody Therapy” to Treat Diabetic Retinopathy.
World Health Organization, Diabetic retinopathy screening: a short guide: The Guide Suggests Optimal Techniques and Procedures Regarding Retinopathic Treatments. and United States, Food and Drug Administration; Main Regulatory Authority Responsible for Inspection and Approval of Companies Providing Healthcare Solutions Across the US. Any New Entrant or Technology should Seek Approval from the USFDA.
- Technical Progress in Medical Industry
- Heavy Investments in Healthcare Research & Development
- Prevalence of Diabetic Conditions Among Adults
- Increasing Screen Time
- Emergence of Advance and Effective Techniques
- Growth in Healthcare infrastructure Due to Pandemic
- Highly Priced Procedures
- Complications Leading to Several Vision Problems
- Lack of Trained Professionals
Key Target Audience
Diabetic Retinopathy Surgical Equipment Manufactures, Hospitals and Clinics, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others
Frequently asked questions:1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.2. How big is the Diabetic Retinopathy Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.